Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The management of severe symptomatic aortic stenosis has been revolutionized by transcatheter aortic valve replacement (TAVR), offering a minimally invasive alternative to surgical aortic valve replacement (SAVR). However, the comparative safety and efficacy of these interventions remain subjects of ongoing investigation.
Aim: To compare the clinical outcomes and safety of TAVR SAVR in patients with severe symptomatic aortic stenosis.
Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. Randomized controlled trials (RCTs) comparing TAVR and SAVR were identified from databases including PubMed, Scopus, and Web of Science up to May 31, 2024. Data were extracted on clinical outcomes, including mortality, procedural complications, and post-procedure adverse events. Risk ratios (RRs) with 95%CIs were calculated using a random-effects model.
Results: A total of 10 RCTs were included. TAVR demonstrated a significantly lower risk of acute kidney injury (RR: 0.33; 95%CI: 0.25-0.44), major bleeding (RR: 0.37; 95%CI: 0.30-0.46), and new-onset atrial fibrillation (RR: 0.44; 95%CI: 0.34-0.57) compared to SAVR. However, TAVR was associated with higher risks of new permanent pacemaker implantation (RR: 3.49; 95%CI: 2.77-4.39), major vascular complications (RR: 2.47; 95%CI: 1.91-3.21), and paravalvular leaks (RR: 4.15; 95%CI: 3.14-5.48). Mortality at 30 days was comparable (RR: 0.95; 95%CI: 0.78-1.15), but long-term mortality was slightly higher with TAVR in some analyses (RR: 1.23; 95%CI: 1.01-1.49). Rates of stroke (RR: 0.97; 95%CI: 0.81-1.17) and myocardial infarction (RR: 0.91; 95%CI: 0.67-1.24) were similar between the groups.
Conclusion: TAVR offers a less invasive option with significant benefits in reducing acute kidney injury, major bleeding, and new-onset atrial fibrillation, making it particularly advantageous for high-risk surgical candidates. However, higher risks of permanent pacemaker implantation, vascular complications, and paravalvular leaks highlight the need for individualized patient selection and shared decision-making to optimize outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038701 | PMC |
| http://dx.doi.org/10.4330/wjc.v17.i4.104168 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Effectiveness of TAVI Platforms and Surgical Aortic Valve Replacement: A Network Meta-Analysis of Randomized Controlled Trials.
Circ Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Standardising cardiac CT-based personalised surgical planning and execution in congenital aortic valvar disease.
Cardiol Young
September 2025
Congenital Valve Procedural Planning Program, Division of Pediatric Cardiac Surgery, Cleveland Clinic Children's, and Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
Background: Congenital aortic valvar disease represents a heterogeneous population with suboptimal surgical repair or replacement outcomes. We assess our approach and short-term outcomes in this population using cardiac CT evaluation for personalised surgical planning and execution.
Methods: We assessed patients who underwent aortic valvar surgery from February 2022 to August 2024.
Outcomes of Fluoroscopy-Based Asymmetric Underexpansion With the Self-Expanding ACURATE Neo and Neo2 Valve.
Catheter Cardiovasc Interv
September 2025
Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Background: Asymmetric underexpansion of transcatheter heart valves (THVs), as observed on fluoroscopy, may influence prosthesis function or long-term durability of transcatheter aortic valve implantation (TAVI).
Aims: This study aimed to evaluate the effect of stent frame asymmetry on hemodynamic performance and clinical outcomes in ACURATE neo and neo2 THVs.
Methods: In a retrospective registry, the TAVI asymmetry index was defined as the ratio of the THV stent frame diameter.
Preoperative Echocardiography in Pectus Excavatum: High Rate of Incidental Findings, Low but Clinically Important Yield of Significant Anomalies.
J Pediatr Surg
September 2025
University of Utah, Department of Surgery, Division of Pediatric Surgery. Electronic address:
Background: Routine preoperative echocardiograms (ECHOs) are frequently obtained in patients undergoing minimally invasive repair of pectus excavatum (MIRPE), but the benefit and necessity of preoperative screening remain debated. In this study, we sought to quantify the proportion of preoperative ECHOs that had clinically significant findings.
Methods: We conducted a retrospective review of 255 patients who underwent MIRPE at a single pediatric referral center from 2018 to 2023.
Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: a substudy from the LAAOS III Trial.
J Thorac Cardiovasc Surg
September 2025
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada.
Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.
Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.